MedTrace Logo

Age-Related Eye Disease Study (AREDS)

NCT00000145 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 4757

Last updated 2009-01-23

No results posted yet for this study

Summary

To assess the clinical course, prognosis, and risk factors of age-related macular degeneration (AMD) and cataract.

To evaluate, in randomized clinical trials, the effects of pharmacologic doses of (1) antioxidants and zinc on the progression of AMD and (2) antioxidants on the development and progression of lens opacities.

Conditions

  • Macular Degeneration
  • Cataract
  • Lens Opacities

Interventions

DIETARY_SUPPLEMENT

Antioxidants

500 milligrams vitamin C; 400 IUs vitamin E; 15 milligrams beta-carotene

DIETARY_SUPPLEMENT

Zinc

80 milligrams zinc oxide; 2 milligrams of cupric oxide

DIETARY_SUPPLEMENT

Antioxidants and zinc

500 milligrams vitamin C; 400 IUs vitamin E; 15 milligrams beta-carotene; 80 milligrams zinc oxide; 2 milligrams of cupric oxide

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    collaborator INDUSTRY

  • National Eye Institute (NEI)

    lead NIH

Principal Investigators

  • Emily Y. Chew, MD · National Eye Institute (NEI)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1990-09-30
Primary Completion
2001-10-31
Completion
2006-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000145 on ClinicalTrials.gov